EditorialWhere do we stand in enzyme replacement therapy in Pompe’s disease?
References (10)
- et al.
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients
Lancet
(2000) - et al.
Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open label study
Neuromuscul Disord
(2010) - et al.
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease
Neuromuscul Disord
(2009) - et al.
A randomized study of alglucosidase Alfa in late onset Pompe’s disease
N Engl J Med
(2010) - et al.
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease
Neurology
(2007)
Cited by (24)
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts
2021, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :The only treatment currently approved for PD is enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). Although most of the studies on ERT support its efficacy in improving survival of PD patients, long-term follow-up studies have shown that ERT does not completely prevent disease progression.6,7 In fact, the experience of hundreds of PD patients treated with ERT has shown that not all patients respond equally well to therapy and that skeletal muscle (one of the major sites of disease and an important target of therapy) is more refractory to treatment than other tissues.8
Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease
2020, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :Patients with classic infantile Pompe disease have an overall better survival and improved quality of life when treated with enzyme replacement therapy (ERT; registered in 2006 as Myozyme, also marketed as Lumizyme), but this therapy has its limitations. Close to 50% of infants still die at a very young age despite ERT, and residual disease remains in the other patients due to insufficient targeting of the skeletal muscles and a neutralizing immune response, particularly in patients that do not produce any endogenous acid GAA.8–13 Another limitation of ERT is the inability to cross the blood-brain barrier.
Hypotonia and Weakness: Levels Above the Lower Motor Neuron
2018, Volpe's Neurology of the NewbornMuscular dystrophies, metabolic and toxic myopathies
2015, Medicine (Spain)Spectrum of metabolic myopathies
2015, Biochimica et Biophysica Acta - Molecular Basis of DiseaseCitation Excerpt :Furthermore, rhGAA treatment reduced the risk of death and of invasive ventilation, compared with an untreated control group [15]. In contrast to the natural course of untreated patients, most of treated infants acquired motor and functional skills and some patients remained ambulant at the age of 11 years [16]. It was thought that ERT started early in life of infantile patients would have led to a shift toward a juvenile or late-onset phenotype, but this was not the fact: these long term survivor infantile patients present peculiar clinical characteristics (such as elongated face and bulbar features) that might be due to the lack of penetrance of rhGAA in the central nervous system (CNS) [17,18].
Glycogen Storage Diseases of Muscle
2015, Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach